AIMS: To investigate the decline of estimated glomerular filtration rate (eGFR) in patients with atrial fibrillation (AF) treated with vitamin K antagonists (VKAs) or non-VKA oral anticoagulants (NOACs). METHODS: Multicentre prospective cohort study including 1667 patients with nonvalvular AF. The eGFR was assessed by the CKD-EPI formula at baseline and during follow-up. The primary endpoint of the study was the median annual decline of eGFR according to VKA (n = 743) or NOAC (n = 924) use. As secondary endpoints, we analysed the transition to eGFR <50 mL/min/1.73 m2 and the eGFR class worsening. RESULTS: Median age was 73.7 ± 9.1 years and 43.3% were women. VKA-treated patients showed an eGFR decline of -2.11 (interquartile range [IQR] -5.68/-0.62), which was -0.27 (IQR -9.00/4.54, P < 0.001 vs VKAs), -1.21 (IQR -9.98/4.02, P = 0.004 vs VKAs) and -1.32 (IQR -8.70/3.99, P = 0.003 vs VKAs) in patients on dabigatran, rivaroxaban and apixaban, respectively. Transition to eGFR <50 mL/min/1.73 m2 was lower in dabigatran- and apixaban-treated patients: odds ratio (OR) 0.492, 95% confidence interval (CI) 0.298-0.813, P = 0.006 and OR 0.449, 95% CI 0.276-0.728, P = 0.001, respectively. A lower rate of eGFR class worsening was found in all groups of NOACs compared to VKAs. No difference between full and reduced dose of NOAC was found. Subgroup analysis showed that the association between NOAC and eGFR changes was markedly reduced in diabetic patients. CONCLUSION: Patients prescribed NOACs showed a lower decline of renal function compared to those prescribed VKAs. This effect was partially lost in patients with diabetes.
AIMS: To investigate the decline of estimated glomerular filtration rate (eGFR) in patients with atrial fibrillation (AF) treated with vitamin K antagonists (VKAs) or non-VKA oral anticoagulants (NOACs). METHODS: Multicentre prospective cohort study including 1667 patients with nonvalvular AF. The eGFR was assessed by the CKD-EPI formula at baseline and during follow-up. The primary endpoint of the study was the median annual decline of eGFR according to VKA (n = 743) or NOAC (n = 924) use. As secondary endpoints, we analysed the transition to eGFR <50 mL/min/1.73 m2 and the eGFR class worsening. RESULTS: Median age was 73.7 ± 9.1 years and 43.3% were women. VKA-treated patients showed an eGFR decline of -2.11 (interquartile range [IQR] -5.68/-0.62), which was -0.27 (IQR -9.00/4.54, P < 0.001 vs VKAs), -1.21 (IQR -9.98/4.02, P = 0.004 vs VKAs) and -1.32 (IQR -8.70/3.99, P = 0.003 vs VKAs) in patients on dabigatran, rivaroxaban and apixaban, respectively. Transition to eGFR <50 mL/min/1.73 m2 was lower in dabigatran- and apixaban-treated patients: odds ratio (OR) 0.492, 95% confidence interval (CI) 0.298-0.813, P = 0.006 and OR 0.449, 95% CI 0.276-0.728, P = 0.001, respectively. A lower rate of eGFR class worsening was found in all groups of NOACs compared to VKAs. No difference between full and reduced dose of NOAC was found. Subgroup analysis showed that the association between NOAC and eGFR changes was markedly reduced in diabetic patients. CONCLUSION:Patients prescribed NOACs showed a lower decline of renal function compared to those prescribed VKAs. This effect was partially lost in patients with diabetes.
Authors: Usman Baber; Virginia J Howard; Jonathan L Halperin; Elsayed Z Soliman; Xiao Zhang; William McClellan; David G Warnock; Paul Muntner Journal: Circ Arrhythm Electrophysiol Date: 2010-11-13
Authors: Michael Böhm; Michael D Ezekowitz; Stuart J Connolly; John W Eikelboom; Stefan H Hohnloser; Paul A Reilly; Helmut Schumacher; Martina Brueckmann; Stephan H Schirmer; Mario T Kratz; Salim Yusuf; Hans-Christoph Diener; Ziad Hijazi; Lars Wallentin Journal: J Am Coll Cardiol Date: 2015-06-16 Impact factor: 24.094
Authors: Nynke Halbesma; Dirk-Sjoerd Kuiken; Auke H Brantsma; Stephan J L Bakker; Jack F M Wetzels; Dick De Zeeuw; Paul E De Jong; Ronald T Gansevoort Journal: J Am Soc Nephrol Date: 2006-08-09 Impact factor: 10.121
Authors: Sergey V Brodsky; Tibor Nadasdy; Brad H Rovin; Anjali A Satoskar; Gyongyi M Nadasdy; Haifeng M Wu; Udayan Y Bhatt; Lee A Hebert Journal: Kidney Int Date: 2011-03-09 Impact factor: 10.612
Authors: Peter Brønnum Nielsen; Deirdre A Lane; Lars Hvilsted Rasmussen; Gregory Y H Lip; Torben Bjerregaard Larsen Journal: Clin Res Cardiol Date: 2014-11-22 Impact factor: 5.460
Authors: Anders Nissen Bonde; Gregory Y H Lip; Anne-Lise Kamper; Laila Staerk; Christian Torp-Pedersen; Gunnar Gislason; Jonas Bjerring Olesen Journal: Thromb Haemost Date: 2017-12-06 Impact factor: 5.249
Authors: Francesco Violi; Daniele Pastori; Francesco Perticone; William R Hiatt; Angela Sciacqua; Stefania Basili; Marco Proietti; Gino R Corazza; Gregory Y H Lip; Pasquale Pignatelli Journal: BMJ Open Date: 2015-05-21 Impact factor: 2.692